Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance, and Announces $750 Million Share Repurchase Program

Baird Downgrades DexCom (DXCM) to Neutral

July 26, 2024 6:18 AM EDT

Baird analyst Jeff Johnson downgraded DexCom (NASDAQ: DXCM) from Outperform to Neutral with a price target of $80.00 (from $161.00).

The analyst comments "Downgrading to Neutral/lowering price target to $80. We struggle to fully understand last night's 2Q miss/sizable cut to 2024... More

DexCom (DXCM) PT Lowered to $95 at UBS

July 26, 2024 5:57 AM EDT

UBS analyst Danielle Antalffy lowered the price target on DexCom (NASDAQ: DXCM) to $95.00 (from $163.00) while maintaining a Buy rating.

The analyst comments "Shares traded down ~37% after-hours due to DXCM's ~3.5% top-line sales miss and now lower (~$300M) FY24 guidance with full-year sales expected to grow +11-13% organic vs. +17-21%, previously. And while this comes as quite a surprise to us given our view that CGM (Continuous Glucose Monitoring)... More

DexCom (DXCM) PT Lowered to $89 at Canaccord Genuity

July 26, 2024 5:40 AM EDT

Canaccord Genuity analyst William J. Plovanic lowered the price target on DexCom (NASDAQ: DXCM) to $89.00 (from $145.00) while maintaining a Buy rating.

The analyst comments "Bottom line: Dexcom reported a surprising Q2 topline miss, and guidance reset, with revenue of $1,004M (+15.3% Y/Y) missing both our $1,049M estimate and consensus of $1,037M. On... More